S2 Table (a) Fully adjusted hazard ratios (HRs) for the association of ChAdOx1-S and BNT162b2 with venous events 1-28 and >28 days after vaccination, within pre-specified subgroups. P values for between subgroup differences were derived using Wald tests. OCP: oral contraceptive. HRT: hormone replacement therapy

		ChAdOx1-S vaccine					BNT162b2 vaccine					
		N (Events)	Post vaccination ≤28 days		Post vaccination >28 days		N (Events)	Post vaccination ≤28 days		Post vaccination	>28 days	
Subgroup		3001	HR (95% CI)1	P value	HR (95% CI) ¹	P value	3133	HR (95% CI)1	P value	HR (95% CI) ¹	P value	
Age groups	18-29 30-39 40-49	40 63 145	2.30 (1.63–3.25) 1.33 (1.01–1.75) 1.32 (1.09–1.61)		1.29 (0.58–2.90) 0.85 (0.46–1.59) 1.52 (1.09–2.13)		29 60 122	0.99 (0.60–1.62) 0.90 (0.65–1.25) 0.96 (0.77–1.21)	0.005	0.99 (0.57–1.71) 0.71 (0.47–1.07) 0.75 (0.56–1.01)	0.839	
	50-59 60-69 70-79	270 618 1124	0.93 (0.81–1.07) 0.87 (0.79–0.96) 0.75 (0.69–0.82)	<0.0001	1.00 (0.77–1.30) 0.89 (0.73–1.07) 0.79 (0.71–0.88)	0.003	237 359 823	0.78 (0.66–0.92) 0.78 (0.69–0.89) 0.69 (0.62–0.77)		0.69 (0.55–0.86) 0.67 (0.55–0.83) 0.73 (0.65–0.82)		
	80-89 >90	546 195	0.79 (0.69–0.89) 0.76 (0.62–0.94)		0.73 (0.63–0.84) 0.75 (0.59–0.95)		1255 248	0.63 (0.56–0.70) 0.80 (0.65–0.99)		0.67 (0.61–0.74) 0.67 (0.55–0.81)		
Sex	Male Female	1338 1663	0.81 (0.75–0.87) 0.90 (0.84–0.97)	0.029	0.74 (0.66–0.82) 0.89 (0.81–0.98)	0.005	1423 1710	0.70 (0.64–0.76) 0.75 (0.70–0.81)	0.150	0.66 (0.60–0.72) 0.74 (0.69–0.81)	0.024	
Ethnicity	White Asian or Asian British Black or Black British	2856 38 53	0.86 (0.82–0.91) 0.51 (0.34–0.77) 0.91 (0.66–1.25)	0.010	0.82 (0.76–0.89) 0.66 (0.38–1.14) 0.62 (0.35–1.10)	0.429	2977 56 42	0.72 (0.68–0.77) 0.69 (0.48–0.98) 0.62 (0.41–0.94)	0.002	0.71 (0.66–0.76) 0.57 (0.38–0.86) 0.61 (0.39–0.97)	0.691	
	Mixed Other Ethnic Groups Unknown Missing	10 17 21 6	0.47 (0.21–1.06) 0.73 (0.37–1.43) 1.11 (0.65–1.89) 2.59 (1.05–6.42)	0.018	0.76 (0.28–2.06) 1.63 (0.80–3.32) 1.14 (0.50–2.58) 1.29 (0.18–9.32)		12 23 15 8	0.74 (0.36–1.51) 1.30 (0.75–2.24) 0.74 (0.36–1.51) 3.85 (1.67–8.87)		0.43 (0.16–1.17) 0.94 (0.48–1.84) 0.68 (0.32–1.47) 1.33 (0.33–5.43)		
Deprivation	1-2 (least) 3-4 5-6 7-8	564 560 625 632	0.76 (0.68–0.85) 0.86 (0.77–0.96) 0.90 (0.81–1.00) 0.87 (0.78–0.97)	0.138	0.76 (0.65–0.89) 0.80 (0.68–0.93) 0.82 (0.71–0.96) 0.80 (0.69–0.93)	0.43	489 576 606 687	0.65 (0.57–0.74) 0.76 (0.67–0.85) 0.70 (0.62–0.79) 0.73 (0.65–0.82)	0.095	0.54 (0.47–0.62) 0.70 (0.62–0.80) 0.67 (0.59–0.76) 0.71 (0.63–0.80)	<0.0001	
Prior thrombocytopenia	9-10 (most) No Yes	609 3001 0	0.91 (0.81–1.01) 0.86 (0.82–0.91) 0.54 (0.35–0.82)	0.030	0.92 (0.79–1.06) 0.82 (0.76–0.89) 0.54 (0.31–0.93)	0.127	770 3132 <5	0.81 (0.72–0.91) 0.73 (0.69–0.78) 0.37 (0.21–0.63)	0.014	0.88 (0.79–0.98) 0.71 (0.66–0.75) 0.58 (0.38–0.89)	0.372	
Prior thrombophilia	No Yes	2986 15	0.86 (0.81–0.91) 0.50 (0.27–0.94)	0.093	0.82 (0.76–0.89) 0.38 (0.14–1.03)	0.130	3116 17	0.73 (0.69–0.77) 0.48 (0.23–0.99)	0.254	0.70 (0.66–0.75) 0.68 (0.34–1.37)	0.924	
Prior venous event	No Yes	3001	0.95 (0.90–1.01) 0.54 (0.48–0.61)	< 0.0001	0.96 (0.88–1.05) 0.42 (0.35–0.50)	< 0.0001	3133	0.80 (0.76–0.86) 0.44 (0.38–0.51)	< 0.0001	0.78 (0.73–0.84) 0.44 (0.38–0.51)	< 0.0001	
Prior COVID infection	No Yes	2839 162	0.88 (0.83–0.93) 0.60 (0.49–0.74)	< 0.001	0.85 (0.79–0.93) 0.49 (0.37–0.64)	< 0.0001	3012 121	0.74 (0.70–0.79) 0.47 (0.36–0.61)	0.001	0.72 (0.68–0.77) 0.45 (0.34–0.58)	< 0.001	
ОСР	No Yes	2996 5	1.15 (0.99–1.35) 0.69 (0.22–2.17)	0.382	1.03 (0.77–1.39) 1.26 (0.31–5.09)	0.786	3129 <5	0.84 (0.70–1.00) 0.33 (0.08–1.34)	0.195	0.77 (0.61–0.97) 0.34 (0.08–1.41)	0.270	
HRT	No Yes	2972 29	0.78 (0.73–0.83) 0.92 (0.56–1.50)	0.514	0.75 (0.69–0.82) 0.96 (0.45–2.05)	0.532	3112 21	0.69 (0.65–0.73) 0.57 (0.30–1.08)	0.554	0.66 (0.62–0.71) 0.65 (0.34–1.23)	0.949	
Anticoagulant	No Yes	2759 242	0.98 (0.92–1.03) 0.34 (0.29–0.40)	< 0.0001	0.98 (0.90–1.07) 0.28 (0.22–0.35)	< 0.0001	2875 258	0.84 (0.79–0.89) 0.25 (0.21–0.31)	< 0.0001	0.83 (0.77–0.89) 0.27 (0.22–0.32)	< 0.0001	
Antiplatelet	No Yes	2503 498	0.89 (0.84–0.95) 0.69 (0.61–0.78)	< 0.001	0.84 (0.77–0.92) 0.73 (0.62–0.85)	0.081	2513 620	0.75 (0.71–0.80) 0.62 (0.55–0.71)	0.011	0.72 (0.67–0.77) 0.66 (0.58–0.75)	0.220	
Prior MI or stroke	No Yes	2603 398	0.88 (0.83–0.93) 0.71 (0.62–0.82)	0.004	0.87 (0.80–0.95) 0.58 (0.48–0.69)	< 0.0001	2680 453	0.74 (0.70–0.79) 0.62 (0.53–0.72)	0.021	0.72 (0.67–0.77) 0.63 (0.55–0.73)	0.086	
Prior diabetes	No Yes	2363 638	0.71 (0.62–0.82) 0.88 (0.83–0.93) 0.78 (0.70–0.87)	0.053	0.85 (0.48–0.93) 0.72 (0.62–0.83)	0.034	2456 677	0.62 (0.53-0.72) 0.74 (0.70-0.79) 0.67 (0.60-0.76)	0.149	0.63 (0.53-0.73) 0.71 (0.66-0.76) 0.69 (0.61-0.78)	0.639	

¹ adjusted

S2 Table (b) Fully adjusted hazard ratios (HRs) for the association of ChAdOx1-S and BNT162b2 with arterial events 1-28 and >28 days after vaccination, within pre-specified subgroups. P values for between subgroup differences were derived using Wald tests. OCP: oral contraceptive. HRT: hormone replacement therapy

			ChA	dOx1-S vac	cine		BNT162b2 vaccine					
	All arterial	N (Events)		Post vaccination ≤28 days		Post vaccination >28 days		Post vaccination ≤28 days		Post vaccination >28 days		
Subgroup		12890	HR (95% CI) ¹	P value	HR (95% CI) ¹	P value	16759	HR (95% CI) ¹	P value	HR (95% CI) ¹	P valu	
Age groups	18-29	12	1.72 (0.89–3.33)		1.84 (0.59–5.73)		21	2.01 (1.13-3.57)		1.85 (0.96-3.59)		
	30-39	54	1.51 (1.11–2.06)		1.54 (0.87-2.72)		67	1.36 (1.00-1.86)		1.09 (0.74-1.61)		
	40-49	277	1.37 (1.20–1.57)	<0.0001	1.29 (0.99-1.69)	0.031	284	1.17 (1.01-1.36)	<0.0001	0.86 (0.70-1.05)	<0.0001	
	50-59	963	0.98 (0.91–1.05)		0.89 (0.76–1.04)		1062	1.06 (0.98–1.14)		0.81 (0.72-0.91)		
	60-69	2442	0.85 (0.81-0.90)		0.90 (0.82-0.99)		1705	0.89 (0.84-0.95)		0.83 (0.76–0.92)		
	70-79	5030	0.90 (0.86-0.94)		0.93 (0.88-0.99)		3993	0.85 (0.81–0.89)		0.91 (0.86-0.96)		
	80-89	2826	0.86 (0.81-0.91)		0.88 (0.82–0.94)		7733	0.74 (0.71–0.78)		0.79 (0.76–0.82)		
	>90	1286	0.85 (0.78–0.93)		0.86 (0.78–0.94)		1894	0.72 (0.66–0.79)		0.78 (0.73–0.84)		
Sex	Male	7116	0.78 (0.75–0.80)	< 0.0001	0.75 (0.71–0.79)	< 0.0001	9292	0.77 (0.74–0.79)	< 0.0001	0.71 (0.68–0.73)	< 0.000	
	Female	5774	0.89 (0.86–0.93)		0.87 (0.83–0.92)		7467	0.85 (0.82–0.88)		0.89 (0.85–0.92)		
	White	11729	0.82 (0.79–0.84)		0.80 (0.77–0.84)		15492	0.80 (0.78–0.82)		0.79 (0.76–0.81)		
Ethnicity	Asian or Asian British	647	0.84 (0.76–0.93)	<0.0001	0.74 (0.64–0.86)	0.180	728	0.75 (0.67–0.84)	<0.0001	0.63 (0.56–0.71)	<0.000	
	Black or Black British	217	0.90 (0.75–1.07)		0.89 (0.70–1.15)		190	0.77 (0.62–0.94)		0.79 (0.64–0.99)		
	Mixed	72	1.19 (0.90–1.57)		0.89 (0.70=1.13)		85	1.10 (0.82–1.49)		0.79 (0.64–0.99)		
Ethnicity	Other Ethnic Groups	113	0.93 (0.73–1.18)		0.90 (0.64–1.28)		83 121	0.89 (0.69–1.15)		0.81 (0.57–1.17)		
	*		` ,		` /			, ,		,		
	Unknown	80	0.88 (0.67–1.16)		0.75 (0.49–1.16)		103	0.87 (0.64–1.18)		1.09 (0.83–1.44)		
	Missing	32	3.01 (1.98–4.57)		1.91 (0.89–4.08)	-0.0001	40	2.87 (1.81–4.56)		2.87 (1.80–4.58)		
Deprivation	1-2 (least)	2498	0.76 (0.71–0.80)	<0.001	0.71 (0.66–0.77)	<0.0001	2788	0.75 (0.71–0.79)	<0.0001	0.69 (0.65–0.73)	<0.0001	
	3-4	2514	0.81 (0.76–0.85)		0.76 (0.71–0.82)		2980	0.76 (0.72–0.81)		0.74 (0.69–0.78)		
	5-6	2683	0.85 (0.81–0.90)		0.79 (0.74–0.85)		3489	0.78 (0.74–0.83)		0.79 (0.75–0.84)		
	7-8	2616	0.83 (0.78–0.87)		0.86 (0.80-0.92)		3693	0.82 (0.78–0.87)		0.83 (0.79–0.88)		
	9-10 (most)	2541	0.89 (0.85-0.95)		0.88 (0.82-0.95)		3772	0.90 (0.85-0.95)		0.85 (0.80-0.89)		
Prior thrombocytopenia	No	12889	0.82 (0.80-0.85)	0.334	0.80 (0.77-0.84)	0.499	16758	0.80 (0.78-0.82)	0.920	0.78 (0.76-0.81)	0.136	
Thor thrombocytopenia	Yes	<5	0.75 (0.61–0.91)		0.73 (0.57–0.95)		<5	0.81 (0.66–1.00)		0.67 (0.54–0.82)		
Prior thrombophilia	No	12864	0.82 (0.80-0.85)	0.059	0.80 (0.77-0.83)	0.620	16735	0.80 (0.78-0.82)	0.499	0.78 (0.76-0.81)	0.098	
	Yes	26	0.48 (0.28-0.84)		0.66 (0.32–1.39)		24	0.66 (0.38-1.15)		0.43 (0.21–0.88)		
Prior venous event	No	12874	0.83 (0.81–0.85)	0.029	0.80 (0.77-0.84)	0.504	16751	0.81 (0.78-0.83)	0.022	0.79 (0.76-0.81)	0.002	
	Yes	16	0.73 (0.66–0.82)		0.77 (0.67–0.88)		8	0.70 (0.63-0.79)		0.66 (0.59-0.74)		
Prior COVID infection	No	12227	0.84 (0.81-0.86)	< 0.0001	0.83 (0.79-0.86)	< 0.0001	16234	0.81 (0.79-0.84)	< 0.0001	0.80 (0.77-0.82)	< 0.000	
	Yes	663	0.63 (0.57-0.70)		0.51 (0.45-0.59)		525	0.57 (0.50-0.65)		0.51 (0.45-0.59)		
ОСР	No	12889	0.91 (0.79-1.05)	0.983	0.89 (0.67–1.18)	< 0.0001	16759	0.91 (0.79-1.06)	< 0.0001	0.94 (0.75-1.16)	< 0.000	
	Yes	<5	0.89 (0.12-6.51)		0.00 (0.00-0.00)		0	0.00 (0.00-0.00)		0.00 (0.00-0.00)		
HRT	No	12832	0.85 (0.82-0.87)	0.202	0.84 (0.80-0.88)	0.020	16671	0.81 (0.78-0.83)	0.061	0.79 (0.76-0.81)	0.070	
	Yes	58	1.01 (0.73–1.40)	0.293	0.79 (0.45–1.37)	0.820	88	1.10 (0.79–1.51)		1.08 (0.77–1.52)		
Anticoagulant	No	10726	0.84 (0.82–0.87)	< 0.001	0.82 (0.78-0.85)	0.015	13715	0.83 (0.81-0.86)	< 0.0001	0.80 (0.77-0.83)	< 0.001	
	Yes	2164	0.74 (0.69–0.79)		0.74 (0.68–0.80)		3044	0.66 (0.62-0.70)		0.71 (0.67–0.76)		
Antiplatelet	No	7636	0.99 (0.96–1.03)	< 0.0001	1.06 (1.01–1.11)	< 0.0001	9770	0.96 (0.93–0.99)	< 0.0001	1.05 (1.01–1.09)	< 0.0001	
	Yes	5254	0.65 (0.63–0.68)		0.59 (0.55–0.62)		6989	0.65 (0.63–0.67)		0.55 (0.53–0.57)		
Prior MI or stroke	No	6931	1.09 (1.05–1.13)		1.18 (1.12–1.24)		9428	1.08 (1.04–1.12)	< 0.0001	1.22 (1.17–1.26)	< 0.0001	
	Yes	5959	0.64 (0.61–0.66)	< 0.0001	0.60 (0.57–0.63)	< 0.0001	7331	0.60 (0.57–0.62)		0.51 (0.49–0.53)		
	No	8742	0.85 (0.83–0.88)		0.84 (0.80–0.88)		11689	0.84 (0.82–0.87)		0.82 (0.79–0.85)		
Prior diabetes			` ′	< 0.0001		< 0.001			< 0.0001	, , , , , , , , , , , , , , , , , , , ,	< 0.0001	
1101 dimberes	Yes	4148	0.77 (0.73–0.80)	~0.0001	0.73 (0.69–0.78)	-0.001	5070	0.72 (0.69–0.76)	~0.0001	0.70(0.67-0.74)		

¹ adjusted